



**TERUMOBCT**  
Unlocking the Potential of Blood

**MIRASOL®**  
PATHOGEN REDUCTION TECHNOLOGY SYSTEM

HELPING YOU KEEP THE BLOOD SUPPLY SAFE  
IS OUR HIGHEST PRIORITY



## PATHOGEN REDUCTION MADE SIMPLE

Safeguarding the blood supply is critical. Pathogen reduction provides you that added measure of security against disease-causing agents, including viruses, parasites, bacteria and white blood cells.

### **Naturally, you want a partner you can trust.**

The Mirasol Pathogen Reduction Technology (PRT) System uniquely uses the properties of riboflavin (vitamin B2) and ultraviolet light to reduce the infectious pathogen load and inactivate residual white blood cells in blood products.\*

The Mirasol system renders pathogens harmless by using a non-mutagenic, non-toxic method, eliminating the need to remove photochemical agents prior to transfusion – making your treated blood products immediately available to treat patients.

Using a single, integrated system for platelets and plasma, Terumo BCT's proprietary process delivers:

**SAFETY | EFFICACY | SIMPLICITY**

\*The Mirasol system has received the CE mark for platelets and plasma and is under development for the treatment of whole blood

# YOUR SYSTEM FOR PLATELETS AND PLASMA

MIRASOL PRT IS THE OBVIOUS CHOICE FOR PATHOGEN REDUCTION



THE MIRASOL SYSTEM IS DESIGNED TO BE EFFECTIVE AGAINST A BROAD RANGE OF PATHOGENS WHILE STILL MAINTAINING THE QUALITY OF APHERESIS AND WHOLE BLOOD-DERIVED BLOOD PRODUCTS. PERFORMANCE DEMONSTRATED AGAINST:

- **VIRUSES:** Enveloped and non-enveloped<sup>1-3</sup>
- **BACTERIA:** Gram negative and gram positive<sup>4</sup>
- **PARASITES**<sup>5-9</sup>

- **WHITE BLOOD CELLS (WBCS):**  
Inactivation of WBCs in donated blood products may reduce immunological complications of transfusion<sup>10-12</sup>

## Safety established

Mirasol-treated components have been shown to be safe for transfusion recipients as well as for those who handle blood products.

- Riboflavin is non-toxic and non-mutagenic; no additional precautionary measures necessary for staff
- Riboflavin and its photoproducts are already present in human blood and do not need to be removed from blood products prior to transfusion<sup>13</sup>
- The safety of the Mirasol process has been demonstrated through extensive toxicology testing<sup>14</sup>
- No adverse events were attributed to the use of Mirasol-treated platelet products or to the use of the Mirasol PRT system in a well-controlled patient trial<sup>15</sup>

## Efficacy maintained

Reduce pathogen load while providing quality platelets and fresh frozen plasma (FFP).

- The MIRACLE clinical trial confirmed no increased need for platelet or red blood cell transfusions in patients receiving Mirasol-treated platelets<sup>15</sup>
- This trial also showed Corrected Count Increments (CCI) remained stable throughout multiple transfusions of Mirasol-treated platelets<sup>15</sup>
- Mirasol-treated FFP preserves levels of coagulants and anticoagulants that meet the Council of Europe guidelines for untreated FFP<sup>16-18</sup>

## Simplicity by design

Easy to learn. Easy to operate. Flexible. Limited handling and minimal product loss with the Mirasol process help keep your operations efficient. In addition, our fully integrated data capture and storage software system, the Mirasol Manager, ensures accurate reporting and simplified data management.



\*Platelet additive solution (PAS) may need to be added after illumination to platelet concentrates with reduced plasma content to ensure adequate storage conditions for up to 5 days

## REFERENCES

1. Ruane PH, et al., "Photochemical Inactivation of Selected Viruses and Bacteria in Platelet Concentrates Using Riboflavin and Light." *Transfusion* 2004; 44: 877-885.
2. Goodrich RP, et al., "The Mirasol PRT System for Pathogen Reduction of Platelets and Plasma: An Overview of Current Status and Future Trends." *Transfusion and Apheresis Science* 2006; 35 (1): 5-17.
3. Goodrich RP, et al., Chapter 5: "The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications to Blood Safety and Transfusion Medicine." *Flavins: Photochemistry and Photobiology*, Vol. 6, 2006, Royal Society of Chemistry; Cambridge, United Kingdom. E Silva and AM Edwards, editors.
4. Goodrich RP, et al., "A Laboratory Comparison of Pathogen Reduction Technology Treatment and Culture of Platelet Products for Addressing Bacterial Contamination Concerns." *Transfusion* 2009; 49: 1205-1216.
5. Cardo LJ, et al., "Pathogen Inactivation of *Leishmania Donovanii* Infantum in Plasma and Platelet Concentrates Using Riboflavin and Ultraviolet Light." *Vox Sanguinis* 2006; 90: 85-91.
6. Sullivan J, et al., "Pathogen Inactivation of *Plasmodium Falciparum* in Plasma and Platelet Concentrates With Riboflavin and UV Light." *Vox Sanguinis* 2008; 95 (Suppl. 1): 278-279.
7. Cardo LJ, et al., "Pathogen Inactivation of *Trypanosoma Cruzi* in Plasma and Platelet Concentrates Using Riboflavin and Ultraviolet Light." *Transfusion and Apheresis Science* 2007; 37 (2): 131-137.
8. Tonnetti L, et al., "Evaluation of the Mirasol Platelet Reduction Technology System Against *Babesia Microti* in Apheresis Platelets and Plasma." *Transfusion* 2010, in press.
9. Rentas F, et al., "Inactivation of *Orientia Tsutsugamushi* in Red Blood Cells, Plasma, and Platelets With Riboflavin and Light, as Demonstrated in an Animal Model." *Transfusion* 2007; 47: 240-247.
10. Fast LD, et al., "Functional Inactivation of White Blood Cells by Mirasol Treatment." *Transfusion* 2006; 46: 642-648.
11. Fast LD, et al., "Mirasol PRT Treatment of Donor White Blood Cells Prevents the Development of Xenogeneic Graft-Versus-Host Disease in Rag2-/- $\gamma$ c-/- Double Knockout Mice." *Transfusion* 2006; 46: 1553-1560.
12. Asano H, et al., "Treatment With Riboflavin and Ultraviolet Light Prevents Alloimmunization to Platelet Transfusions and Cardiac Transplants." *Transplantation* 2007; 84 (9): 1174-1182.
13. Hardwick CC, et al., "Separation, Identification and Quantification of Riboflavin and Its Photoproducts in Blood Products Using High-Performance Liquid Chromatography With Fluorescence Detection: A Method to Support Pathogen Reduction Technology." *Photochemistry and Photobiology* 2004; 80 (3): 609-615.
14. Reddy HL, et al., "Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation." *Transfusion Medicine Reviews* 2008; 22 (2): 133-153.
15. The Mirasol Clinical Evaluation Study Group, "A Randomized Controlled Clinical Trial Evaluating the Performance and Safety of Platelets Treated With Mirasol Pathogen Reduction Technology." *Transfusion* 2010, in press.
16. Smith J and G Rock, "Protein Quality in Mirasol Pathogen Reduction Technology-Treated, Apheresis-Derived Fresh-Frozen Plasma." *Transfusion* 2010; 50: 926-931.
17. Hornsey VS, et al., "Pathogen Reduction of Fresh Plasma Using Riboflavin and Ultraviolet Light: Effects on Plasma Coagulation Proteins." *Transfusion* 2009 49: 2167-2172.
18. Larrea L, et al., "The Influence of Riboflavin Photochemistry on Plasma Coagulation Factors." *Transfusion and Apheresis Science* 2009; 41: 199-204.

## **LEARN MORE**

The Mirasol PRT system can help you provide safer blood products today. Contact your Terumo BCT sales representative or visit [TERUMOBCT.COM](http://TERUMOBCT.COM) for additional information.

# TERUMOBCT

Unlocking the Potential of Blood

## **Terumo BCT, Inc.**

10811 West Collins Ave.  
Lakewood, Colorado 80215-4440  
USA

USA Phone: 1.877.339.4228  
Phone: +1.303.231.4357  
Fax: +1.303.542.5215

## **Terumo BCT Europe N.V.**

Europe, Middle East and Africa  
Ikaroslaan 41  
1930 Zaventem  
Belgium

Phone: +32.2.715.05.90  
Fax: +32.2.721.07.70

## **Terumo BCT (Asia Pacific) Ltd.**

Room 3903-3903A, 39/F  
ACE Tower, Windsor House  
311 Gloucester Road  
Causeway Bay, Hong Kong

Phone: +852.2283.0700  
Fax: +852.2576.1311

## **Terumo BCT Latin America**

Juncal 1311 4th Floor  
C1062ABO  
Buenos Aires  
Argentina

Phone: +54.11.5530.5200  
Fax: +54.11.5530.5201

©2012 Terumo BCT, Inc. / PN 306690232

**UNLOCKING THE POTENTIAL OF BLOOD | TERUMOBCT.COM**